Comparison
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 vs 3 Methylglutaconic Aciduria Type 3 C0574084
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Endogenous Maternal Derived Androgen and 3 Methylglutaconic Aciduria Type 3 for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
A condition where hormones from the mother cross the placenta and cause atypical development in an XX fetus. It is present at birth. Management involves pediatric specialists and may include hormone therapy.
3 Methylglutaconic Aciduria Type 3 C0574084
A genetic metabolic disorder that primarily affects the nervous system, often causing vision problems, movement difficulties, and cognitive challenges. Treatment involves supportive therapies and regular monitoring.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
Variable
3 Methylglutaconic Aciduria Type 3 C0574084
1-10
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
severe
3 Methylglutaconic Aciduria Type 3 C0574084
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
Chronic
3 Methylglutaconic Aciduria Type 3 C0574084
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
No
3 Methylglutaconic Aciduria Type 3 C0574084
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
reproductive
3 Methylglutaconic Aciduria Type 3 C0574084
metabolic
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
endocrine
3 Methylglutaconic Aciduria Type 3 C0574084
metabolic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-endogenous-maternal-derived-androgen-C5679875 and 3-methylglutaconic-aciduria-type-3-C0574084 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 | 3 Methylglutaconic Aciduria Type 3 C0574084 | Discriminating power |
|---|---|---|---|
| Genital development | Atypical genital development may be present at birth in an XX fetus. | Genital development is not the described primary feature. | High |
| Neurologic and visual problems | Not established as a core feature from the supplied description. | Vision, movement, and cognitive challenges are commonly described. | High |
| Onset pattern | Present at birth, with variable later clinical course. | Reported onset range is 1–10 years. | Moderate |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 when
Atypical genitalia in a newborn with 46,XX findings
This pattern fits a disorder of sex development rather than a primary metabolic neurologic disorder.
High
Suspected maternal androgen exposure during pregnancy
The supplied etiology specifically involves endogenous maternal-derived androgen crossing the placenta.
Moderate
Need for pediatric endocrine and DSD care
Management is described as specialist-led and may include hormone therapy.
Moderate
Choose 3 Methylglutaconic Aciduria Type 3 C0574084 when
Childhood vision, movement, or cognitive concerns
These are the principal features described for type 3.
Moderate
Suspected inherited metabolic disease
The condition is categorized as genetic and metabolic, not reproductive.
High
Onset during ages 1–10 without genital atypicality
This timing better matches the supplied onset axis.
Moderate
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 | 3 Methylglutaconic Aciduria Type 3 C0574084 | Interpretation |
|---|---|---|---|
| Karyotype or sex-chromosome analysis | 46,XX may support the named developmental context. | No characteristic karyotype abnormality is established here. | A karyotype does not prove maternal androgen causation. |
| Urine organic acid analysis | No characteristic organic acid pattern is supplied. | Elevated 3-methylglutaconic acid may be sought; cutoffs are not specified. | An abnormal metabolite result is not itself a complete diagnosis. |
| Targeted genetic evaluation | Testing may investigate maternal endocrine causes rather than a fetal metabolic gene. | Specialist genetic testing may be considered for the metabolic disorder. | Gene selection and interpretation belong to clinicians. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
- Outcome
- A severe chronic developmental condition is described, but individual outcome is not established.
- Factors
- Timing of recognition, endocrine findings, and specialist management may influence care.
3 Methylglutaconic Aciduria Type 3 C0574084
- Outcome
- A moderate chronic neurologic-metabolic course is described, with variable functional impact.
- Factors
- Vision, movement, cognition, and access to supportive care are relevant.
Time frame: Left is present from birth; right onset is listed as 1–10 years. Long-term outcomes are not quantified.
Neither condition is communicable. Prognosis should be individualized by clinicians.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental and identity-related concerns | Possible effects relate to atypical sex development and endocrine care. Not the primary complication described. Exact frequency and outcomes are not established. |
| Vision and movement impairment | Not established from the supplied evidence. Vision problems and movement difficulties are described. Severity varies; no mortality or progression rate is supplied. |
| Need for long-term specialist follow-up | Pediatric endocrine and DSD follow-up may be needed. Supportive therapy and regular monitoring are described. Both are chronic, but care pathways differ. |
Patient education highlights
- HighDifferent conditions
One concerns fetal sex development from maternal androgen exposure; the other is a genetic metabolic neurologic disorder.
- HighDiagnosis limits
An abnormal examination or laboratory result does not automatically confirm either diagnosis.
- MediumCare planning
Ask clinicians about specialist referral, monitoring, and supportive or hormone therapy without assuming a specific dose.